17 Amgen medicines are selling at a pace above $1 billion a year
Amgen reported Q3 2026 revenues of $10.4B, up 8% YoY, with 17 products annualizing over $1B in sales. GAAP EPS rose 19% to $5.93, and non-GAAP EPS increased 14% to $5.64. Key growth drivers included Repatha (up 37%) and EVENITY (up 39%), while Prolia saw a 45% decline due to biosimilar competition.
How this was made
The 30-second read
Why it matters
The earnings beat reinforces Amgen's growth narrative, likely prompting short‑term buying and sector‑wide optimism.
Market read
Large‑cap biotech earnings with double‑digit growth provide a clear trading catalyst for AMGN and related stocks.
What to watch
Potential headwinds from biosimilar competition on key products like Prolia and XGEVA may dampen future growth.
Background
Amgen's Q3 2026 earnings release highlights product‑level performance across its portfolio, including strong growth in several biologics and mixed results in others.
Ticker impact
Amgen reported Q3 2026 earnings with double‑digit sales growth and $10.4B revenue, marking the first public disclosure of these results.
likely upside as investors price in better‑than‑expected sales and EPS growth
The press release provides fresh, material financial metrics for a large‑cap biotech, which typically moves the stock on earnings day.
Market effects
Biotech sector may see broader rally on Amgen's strong performance, supporting peers with similar pipelines.
U.S. market gains from a major pharma earnings beat.
Amgen's results could influence global biotech sentiment and fund allocations.
Counterpoint
If guidance falls short of expectations despite revenue growth, the stock could face profit‑taking pressure.
Key entities
- executiveRobert A. Bradway
Chairman and CEO of Amgen, quoted on growth strategy.
